Colgate-Palmolive Co (CL)
適正価値ファンダメンタル
55
株価
$84.64
時価総額
$68.97B
パート1 · 企業の価値
概要
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals. It also offers pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand; and a fresh pet food sold to pet specialty and other retailers in Australia under Prime100 brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
P&G sells to the same supermarket shoppers in nearly every Colgate category, with Crest and Oral-B against Colgate toothpaste and toothbrushes, Olay and Old Spice against Palmolive and Softsoap, and Dawn and Tide against Colgate's home-care lines.
Church & Dwight targets the same US household shopper with TheraBreath mouthwash and Arm & Hammer toothpaste against Colgate's oral care, and with Arm & Hammer and OxiClean against its cleaning brands.
Unilever fights Colgate for the same shelf space in oral care (Closeup, Pepsodent) and personal care (Dove, Lifebuoy), above all in the emerging markets that generate a large share of Colgate's sales.
Haleon is the main rival in premium therapeutic oral care, where Sensodyne, Parodontax and Polident compete directly with Colgate Sensitive, Colgate Total and Colgate's denture-care products, often on pharmacist and dentist recommendation.
Through Purina and Purina Pro Plan Veterinary Diets, Nestlé is the largest player in the pet food aisles and veterinary clinics where Colgate's Hill's Science Diet and Prescription Diet earn roughly a quarter of group sales.
Reckitt competes for the same home-care and hygiene budget, with Lysol, Finish and Air Wick facing Colgate's Ajax, Fabuloso, Axion and Suavitel across the US, Europe and Latin America.
貸借対照表と流動性
売上高
$21.05B
直近12か月（2026/6/30まで）
純利益
$2.04B
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$3.63B
自己資本合計
$54M
負債合計
$15.96B
流動比率
1.03
利払い倍率
12.32
負債/EBITDA
1.99
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$71.98
現在株価
$84.64
安全マージン
-17.6%
適正価値レンジ
$46.79 - $97.17
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
33.72
ROE
3948.1%
P/B レシオ
288.20
P/FCF
17.63
粗利益率
60.4%
ROIC
23.2%
収益性レーダー
価値創造（経済的モート）
ROIC
23.2%
WACC
7.5%
ROIC − WACC
+15.8 pp
ROICが資本コストを上回っています。企業は株主のために価値を創出しています。
ファンダメンタル分析基準
合格（14）
- ROIC 23.2%
- Gross Margin 60.4%
- P/FCF 17.63
- Operating Margin 14.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 631.1%
- Analyst Consensus 65% Buy
- Earnings Quality (OCF/NI) 2.19
- Share Dilution -1.5%
不合格（12）
- EPS shows upward trend
- EPS CAGR -1.08%
- Price CAGR 2.87%
- P/B Ratio 288.20
- Debt/Equity ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 4.3%
- Earnings Surprise avg 0.4%
- Net Margin Trend 9.7% vs 14.5%
- Piotroski F-Score 4/9
データなし（2）
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Noel R. Wallace | Chairman, CEO & President | 61 |
| Mr. Stanley J. Sutula III | Chief Financial Officer | 59 |
| Mr. Panagiotis Tsourapas | COO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | 60 |
| Mr. Shane Grant | Chief Operating Officer of Americas | 50 |
| Mr. Stephan Habif | Chief Technology Officer | - |
| Mr. David Foster | Chief Information Officer | - |
| Mr. John Faucher | Chief Investor Relations Officer and Executive VP of M&A | - |
| Ms. Betsy Fishbone | EVP, Chief Legal Officer & Secretary | - |
| Mr. Eutychus Karuru | Executive Vice President of Internal Audit & Compliance | - |
| Mr. Dana Bolden | Chief Communications Officer | 57 |
監査リスク
3
取締役会リスク
5
報酬リスク
4
株主権利リスク
2
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for CL, sourced from Markets Gazette.